Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803
NEWS
Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos will deprioritize the development of inupadenant after it failed to meet the biotech’s clinical bar in a Phase II study of metastatic non-small cell lung cancer.
Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can effectively mitigate the impacts of Jakafi’s loss of exclusivity in the coming years, according to analysts.
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
Another busy week for clinical trial news. Here’s a look.
It was another busy week for clinical trial announcement. Here’s a look.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
AWARDS
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS